• SPX
  • $5,893.62
  • 0.39 %
  • $23.00
  • DJI
  • $43,389.60
  • -0.13 %
  • -$55.39
  • N225
  • $38,414.21
  • 0.51 %
  • $193.58
  • FTSE
  • $8,109.32
  • 0.57 %
  • $45.71
  • IXIC
  • $18,791.81
  • 0.6 %
  • $111.69
App Store Download on the App Store Google Play GET IT ON Google Play

Get The App

App Store Download on the App Store Google Play GET IT ON Google Play

Daiichi Sankyo, Merck Phase 3 Lung-Cancer Study Meets Primary Endpoint

By MarketWatch   |   Sep 17, 2024 at 06:29 AM EST
Daiichi Sankyo, Merck Phase 3 Lung-Cancer Study Meets Primary Endpoint

Merck & Co. and Daiichi Sankyo announced success in a late-stage lung cancer study with their drug candidate, patritumab deruxtecan.

Read More

Did you find this insightful?


We are preparing, please wait

×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In

or
download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Sign Up With Email Address
or
google app download Continue with Google ios app download Continue with Apple

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.